High rate of hepatitis due to treatment with pyrazinamide (PYR) and ethambutol (EMB) for latent tuberculosis infection (LTBI) in subjects exposed to MDR-TB Source: Annual Congress 2005 - Management of tuberculosis pulmonary, extrapulmonary peculiarities Year: 2005
Latent tuberculosis (infection). Evaluation of a short course treatment with isoniazid, rifampin and pyrazinamid Source: Eur Respir J 2002; 20: Suppl. 38, 567s Year: 2002
Therapeutic drug monitoring of isoniazid, rifampin, and pyrazinamide in HIV-infected patients with tuberculosis Source: Annual Congress 2012 - Tuberculosis: clinical findings III Year: 2012
Tuberculosis (TB) relapse rate among patients treated with moxifloxacin (m) or ethambutol (E) in the intensive phase of therapy Source: Annual Congress 2009 - Treatment of tuberculosis at times of emerging drug resistance Year: 2009
Tolerance to rifampicine (RIF) 4 months vs. isoniazid (INH) 6 months for latent tuberculosis infection (LTBI) Source: Annual Congress 2008 - Clinical epidemiology of tuberculosis Year: 2008
A UK cost comparison of amikacin therapy with bedaquiline, for drug resistant tuberculosis Source: Virtual Congress 2020 – Multidrug-resistant tuberculosis Year: 2020
Efficacy and safety of linezolid for the treatment of multidrug resistant tuberculosis (MDR-TB) and disease by non tuberculous mycobacteria (NTM) Source: Annual Congress 2011 - Treatment of tuberculosis and adverse drug reactions Year: 2011
Multi drug resistant (rifampicin + isoniazid) pulmonary tuberculosis – a challenge for a developing country specially co-infected with HIV Source: Eur Respir J 2007; 30: Suppl. 51, 421s Year: 2007
Effectiveness of the WHO regimen for treatment of multidrug resistant tuberculosis (MDR-TB) Source: Annual Congress 2013 –Drug-resistant tuberculosis: new clinical and public health insights Year: 2013
Administration of linezolid, bedaquiline and imipenem in treatment of patients with extensively drug-resistant tuberculosis Source: International Congress 2015 – TB treatment: new drugs and drug resistance Year: 2015
Cost-effectiveness analysis of regimens chemotherapy in patients with multidrug resistant tuberculosis (MDR TB) compared with standard regimen in patients with susceptible MBT Source: Eur Respir J 2003; 22: Suppl. 45, 526s Year: 2003
A study on the clinical efficacy of a combination regimen with azithromycin and capreomycin in the treatment of multi-drug resistant pulmonary tuberculosis Source: Eur Respir J 2004; 24: Suppl. 48, 722s Year: 2004
Efficacy of anti-tuberculosis therapy with INH, RIF and Bedaquiline in mice with different genetic susceptibility to the infection Source: International Congress 2019 – Tuberculosis: from basic science to patient care Year: 2019
Susceptibility of mycobacterium avium complex and mycobacterium xenopi to rifampin, rifapentine, clarithromycin and moxifloxacin, alone or in combination with ethambutol Source: Annual Congress 2011 - Treatment of tuberculosis and adverse drug reactions Year: 2011
Two months isoniazid, rifampin and pirazinamid for latent tuberculosis infection Source: Annual Congress 2010 - Special treatment options in tuberculosis Year: 2010
Moxifloxacin, as an alternative in the treatment of patients with the newly diagnosed pulmonary TB with monoresistance to pirazinamid, or its intolerance Source: Virtual Congress 2021 – The ongoing threat of drug-resistant tuberculosis Year: 2021
Rapid molecular detection of rifampicin and isoniazid resistance and identification of mutations in resistant genes of multi-drug resistant tuberculosis (MDR-TB) patients Source: Annual Congress 2011 - Novel strategies for the diagnosis of tuberculosis Year: 2011
Long term plasma rifampicin (R) concentrations in AIDS patients with tuberculosis (TB) under HAART therapy Source: Eur Respir J 2003; 22: Suppl. 45, 40s Year: 2003
Dosage of isoniazid and rifampicin poorly predicts drug exposure in tuberculosis patients Source: Eur Respir J 2016; 48: 1237-1239 Year: 2016
Direct molecular testing for isoniazid and rifampicin resistance from respiratory specimens of patients with tuberculosis Source: Annual Congress 2013 –Tuberculosis: epidemiology and public health management III Year: 2013